Understanding KSHV Inflammatory Cytokine Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather genetic and medical information from individuals diagnosed with KSHV inflammatory cytokine syndrome (KICS), a condition caused by the Kaposi sarcoma-associated herpesvirus (KSHV). Participants will undergo regular study visits where they will provide a complete medical history and undergo physical examinations. The study focuses on assessing the natural history of KICS, including the clinical, laboratory, and radiographic abnormalities associated with the syndrome. By collecting this data, researchers hope to better understand the disease and its progression.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Age greater than or equal to18 Years.
* Any HIV status.
* At least two manifestations drawn from at least two of the categories (clinical symptoms, laboratory abnormalities and/or radiographic abnormalities), which are at least possibly attributable to KICS and are not readily explicable from known medical conditions in the participant:
* Clinical symptoms (each at least grade 1 by CTCAE definitions)
* Fever (\>38 degrees C), chills or rigors
* Fatigue or lethargy
* Cachexia or edema
* Cough, dyspnea, airway hyperreactivity, or nasal inflammation
* Nausea, anorexia, abdominal pain or altered bowel habit
* Athralgia or myalgia
* Altered mental state
* Neuropathy with or without pain
* Laboratory abnormalities
* Anemia (hemoglobin\<12.0g/dL)
* Thrombocytopenia (platelets\<100,000 cells/microL)
* Leukopenia (white cell count\<4,000 cells/microL)
* Hypoalbuminemia (albumin\<3.5g/dL)
* Hyponatremia (sodium\<135mmol/L)
* Coagulopathy (PT or PTT \>1.5 times upper limit of normal)
* Radiographic abnormalities
* Pathologic lymphadenopathy (at least five discrete nodes each \>1cm in their longest dimension)
* Splenomegaly (\>12 cm in the longest dimension)
* Hepatomegaly (\>17cm in the longest dimension)
* Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions directly related to lymphatic infiltration by KS
* C-reactive protein (CRP) \>3mg/L.
* Exposure risk for KSHV infection (including being a first or second generation immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV infection demonstrated by one of:

  * Molecular evidence of KSHV in whole blood, or KSHV VL levels within circulating PBMCs as determined by the Whitby laboratory
  * Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA or vIL-6) confirmed in the Laboratory of Pathology (LP), CCR, NCI.
  * Presence of KS or PEL (KSHV-associated malignancies), confirmed in the LP, CCR, NCI.
* Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and after treatment (if received), according to drug requirements. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

EXCLUSION CRITERIA:

\- Biopsy proven KSHV-associated MCD, confirmed in the LP, CCR, NCI.

Note: In collaboration with LP, we have recently found that some participants with KICS but without a lymph node or splenic diagnosis of MCD have MCD-like cells in their effusions or circulating blood. This may in fact represent a newly recognized form of KSHV-MCD, but our analysis continues. While certain of these participants were historically included in this study, given this new understanding, they will not be entered on this protocol and removed if liquid MCD is diagnosed.

* Pregnancy
* Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to HIV, its treatment, or to KICS that would preclude the use of all of the study treatments or the ability to monitor the natural history of KICS untreated.
* Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Robert Yarchoan, M.D. — National Cancer Institute (NCI)
• Study coordinator: Ijeoma M Agwu
• Email: ijeoma.agwu@nih.gov
• Phone: (240) 858-7435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing pacritinib for treating KSHV-related diseases

  This study is testing if the drug pacritinib can help people with KSHV-related diseases like Kaposi sarcoma and multicentric Castleman disease feel better and reduce inflammation.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06052618

• VLCPUFA-rich fish oil and standard DHA oil: who reaches a higher omega-3 index?

  This study tests whether VLCPUFA-rich fish oil raises the blood omega-3 index more than a standard DHA-rich fish oil in healthy adults aged 18–60.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07882160

• Blood biomarkers for immune-related neuropsychiatric conditions

  This study tests whether blood biomarkers can help identify neuropsychiatric disorders that may be linked to the immune system in people of any age.

  Recruiting at 3 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 2 other locations · NCT07877246

• First-in-human imaging of PDE4D with [11C]JMJ-129-d2 in healthy volunteers

  A new PET tracer called [11C]JMJ-129-d2 is being tested in healthy adults to see if it safely and reliably images the brain’s PDE4D enzyme and to measure how the tracer distributes in the body.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07853781

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Augmenting Parent Management Training with a Smartphone Tool

  This study tests whether adding a smartphone app to parent management training helps reduce irritability and temper outbursts in kids aged 8–13 with disruptive behavior disorders.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07764536

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.